Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Integrated Disease Surveillance and Response (IDSR) in Malawi: Implementation gaps and challenges for timely alert.

Joseph Wu TS, Kagoli M, Kaasbøll JJ, Bjune GA.

PLoS One. 2018 Nov 29;13(11):e0200858. doi: 10.1371/journal.pone.0200858. eCollection 2018.

2.

Sub-national variation in measles vaccine coverage and outbreak risk: a case study from a 2010 outbreak in Malawi.

Kundrick A, Huang Z, Carran S, Kagoli M, Grais RF, Hurtado N, Ferrari M.

BMC Public Health. 2018 Jun 15;18(1):741. doi: 10.1186/s12889-018-5628-x.

3.

Measles seroprevalence in Chiradzulu district, Malawi: Implications for evaluating vaccine coverage.

Polonsky JA, Juan-Giner A, Hurtado N, Masiku C, Kagoli M, Grais RF.

Vaccine. 2015 Aug 26;33(36):4554-8. doi: 10.1016/j.vaccine.2015.07.007. Epub 2015 Jul 26.

4.

Exploring HIV infection and susceptibility to measles among older children and adults in Malawi: a facility-based study.

Polonsky JA, Singh B, Masiku C, Langendorf C, Kagoli M, Hurtado N, Berthelot M, Heinzelmann A, Puren A, Grais RF.

Int J Infect Dis. 2015 Feb;31:61-7. doi: 10.1016/j.ijid.2014.12.010. Epub 2014 Dec 12.

5.

Cholera outbreaks in Malawi in 1998-2012: social and cultural challenges in prevention and control.

Msyamboza KP, Kagoli M, M'bang'ombe M, Chipeta S, Masuku HD.

J Infect Dev Ctries. 2014 Jun 11;8(6):720-6. doi: 10.3855/jidc.3506.

6.

Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay.

Zhang G, Cai F, Zhou Z, DeVos J, Wagar N, Diallo K, Zulu I, Wadonda-Kabondo N, Stringer JS, Weidle PJ, Ndongmo CB, Sikazwe I, Sarr A, Kagoli M, Nkengasong J, Gao F, Yang C.

J Clin Microbiol. 2013 Nov;51(11):3666-74. doi: 10.1128/JCM.01669-13. Epub 2013 Aug 28.

7.

Lessons and challenges for measles control from unexpected large outbreak, Malawi.

Minetti A, Kagoli M, Katsulukuta A, Huerga H, Featherstone A, Chiotcha H, Noel D, Bopp C, Sury L, Fricke R, Iscla M, Hurtado N, Ducomble T, Nicholas S, Kabuluzi S, Grais RF, Luquero FJ.

Emerg Infect Dis. 2013 Feb;19(2):202-9. doi: 10.3201/eid1902.120301.

8.

Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.

Wadonda-Kabondo N, Bennett D, van Oosterhout JJ, Moyo K, Hosseinipour M, Devos J, Zhou Z, Aberle-Grasse J, Warne TR, Mtika C, Chilima B, Banda R, Pasulani O, Porter C, Phiri S, Jahn A, Kamwendo D, Jordan MR, Kabuluzi S, Chimbwandira F, Kagoli M, Matatiyo B, Demby A, Yang C.

Clin Infect Dis. 2012 May;54 Suppl 4:S362-8. doi: 10.1093/cid/cir987.

9.

Re-treatment tuberculosis cases categorised as "other": are they properly managed?

Tweya H, Kanyerere H, Ben-Smith A, Kwanjana J, Jahn A, Feldacker C, Gareta D, Mbetewa L, Kagoli M, Kalulu MT, Weigel R, Phiri S, Edginton M.

PLoS One. 2011;6(12):e28034. doi: 10.1371/journal.pone.0028034. Epub 2011 Dec 14.

Supplemental Content

Loading ...
Support Center